At MBR Health, research is not separate from clinical practice. Our work is focused on improving and quantifying diagnostic fidelity, developing advanced imaging protocols and refining image-guided regenerative treatments — so innovation translates into clearer decisions and more precise care.
Our research and innovation programme spans in-house MRI sequence development, spectral CT protocol optimisation, quantitative imaging, regenerative medicine and clinical publication. The aim is not novelty, but better diagnosis, safer treatment selection and meaningful patient outcomes.
In-house MRI protocol and sequence development for high-resolution anatomy, nerve imaging, dynamic assessment and oncology-calibrated whole-body MRI.
Spectral CT protocol development for tissue characterisation, lesion assessment, iodine mapping and oncology-focused diagnostic pathways.
New technology is not automatically better medicine. The value comes from asking whether a protocol improves detection, characterisation, safety, targeting or treatment selection. Our research focus is built around that question: does this make the diagnosis clearer, the treatment more precise or the follow-up more meaningful?
RESEARCH-GRADE DEXA BODY COMPOSITION Research at MBR Health is grounded in clinical consequence.
We develop and refine techniques because routine pathways do not always answer the most important question with enough precision.
Ultra-high Dose Platelet-rich Plasma Research and innovation at MBR Health is conducted with attention to clinical governance, patient selection, consent, safety and evidence. Emerging techniques are considered within the limits of current evidence and do not replace personalised medical assessment.
